Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kvols, L. K.
Right arrow Articles by Lamberts, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kvols, L. K.
Right arrow Articles by Lamberts, S. W.

Radiology, Vol 187, 129-133, Copyright © 1993 by Radiological Society of North America

ARTICLES

Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors

LK Kvols, ML Brown, MK O'Connor, JC Hung, RJ Hayostek, JC Reubi and SW Lamberts
Department of Oncology, Mayo Clinic, Rochester, MN 55905.

The purpose of this study was to evaluate the usefulness of a radiolabeled analog of somatostatin (iodine-123 octreotide) in the detection and localization of known carcinoid and islet cell tumors and to correlate tumor uptake with the presence or absence of somatostatin receptors. I-123 octreotide studies were performed in 28 patients. Whole-body and tomographic studies were performed over a 2-day period after injection. Twenty-two of the 28 patients underwent tumor biopsy, and samples were analyzed for the presence of somatostatin receptors. Tumors were best seen on scans obtained 1-4 hours after injection. Of the 28 patients, 22 had positive scans with uptake in tumors, three showed photon-deficient uptake in regions of known tumor, and three had negative scans. Seventeen patients in whom results of tumor biopsy were positive for somatostatin receptors had positive scans, and one patient in whom results of biopsy were negative for somatostatin receptors had a negative scan. Previously unsuspected lesions were detected on the I- 123 octreotide scans in four of the 28 patients. I-123 octreotide appears to be a useful tracer for the localization of neuroendocrine tumors and, most likely, other soft-tissue tumors as well.


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
M. H Kulke
Gastrointestinal neuroendocrine tumors: a role for targeted therapies?
Endocr. Relat. Cancer, June 1, 2007; 14(2): 207 - 219.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. P. Norenberg, B. J. Krenning, I. R.H.M. Konings, D. F. Kusewitt, T. K. Nayak, T. L. Anderson, M. de Jong, K. Garmestani, M. W. Brechbiel, and L. K. Kvols
213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model
Clin. Cancer Res., February 1, 2006; 12(3): 897 - 903.
[Abstract] [Full Text] [PDF]

Home page
 ImagingHome page
N Power and R H Reznek
Imaging pancreatic islet cell tumours
Imaging, April 1, 2002; 14(2): 147 - 159.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1993 by the Radiological Society of North America.